New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease

Author's Avatar
Oct 10, 2018
Article's Main Image

- Survival estimates from the EMPA-REG OUTCOME® trial data demonstrate potential long-term benefit of Jardiance (empagliflozin) on life expectancy of adults with type 2 diabetes and cardiovascular disease

PR Newswire